Antabio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $27M

  • Investors
  • 11

Antabio General Information

Description

Operator of a privately-held clinical stage biopharmaceutical company designed for novel and highly differentiated antibacterial treatments of drug-resistant infections. The company's focus is on critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases, enabling health professionals to get access to medicinal products that help in curing drug-resistant diseases.

Contact Information

Website
www.antabio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • 436, Rue Pierre et Marie Curie
  • 31670 Labege
  • France
+33 05 00 00 00 00

Antabio Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antabio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 09-Jun-2023 $27M 000.00 Completed Product In Beta Test
8. Grant 01-Feb-2023 00.00 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A) 06-Apr-2022 000.00 000.00 000.00 Completed Pre-Clinical Trials
6. Grant 01-Dec-2021 00.000 000.00 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 12-Jul-2018 000.00 000.00 000.00 Completed Pre-Clinical Trials
4. Grant 25-Jul-2017 00.00 00.000 Completed Pre-Clinical Trials
3. Seed Round 31-Dec-2015 00.000 00.000 00.000 Completed Product In Beta Test
2. Grant 01-Jan-2015 $4.91M Completed Pre-Clinical Trials
1. Grant 01-Jan-2013 $6.17M Completed Product In Beta Test
To view Antabio’s complete valuation and funding history, request access »

Antabio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A2 Shares 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
A2 Shares 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.00
Ordinary 4,440 $1.100521 $247.87 $247.87 1x $247.87 6.24%
Ordinary 3,021 $1.100521 $182.1 $182.1 1x $182.1 4.25%
To view Antabio’s complete cap table history, request access »

Antabio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a privately-held clinical stage biopharmaceutical company designed for novel and highly differentiated antib
Drug Discovery
Labege, France
14 As of 2023
000.00
00000000000 000.00

00000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000 000000000
San Diego, CA
0 As of 0000
000.00
000000 - 000 000.00

000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Basel, Switzerland
00 As of 0000
00000
00000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antabio Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Forge Therapeutics Formerly PE-Backed San Diego, CA 0 000.00 000000 - 000 000.00
000000000 Venture Capital-Backed Basel, Switzerland 00 00000 00000 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
000000 000000 Formerly VC-backed Marseille, France 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Lorrach, Germany 00 000.00 00000000000 000.00
You’re viewing 5 of 7 competitors. Get the full list »

Antabio Patents

  • 48

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Antabio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4125883-A1 Combination therapy Inactive 24-Mar-2020 000000000
EP-3670512-A1 Diazabicyclooctanones as inhibitors of serine beta-lactamases Inactive 18-Dec-2018 0000000000 0
US-20220112169-A1 Indane derivatives for use in the treatment of bacterial infection Pending 25-Sep-2018 000000000
AU-2019351551-A1 Indane derivatives for use in the treatment of bacterial infection Pending 25-Sep-2018 0000000000
AU-2019349438-A1 Indane derivatives for use in the treatment of bacterial infection Pending 25-Sep-2018 C07D277/64
To view Antabio’s complete patent history, request access »

Antabio Executive Team (5)

Name Title Board Seat Contact Info
Marc Lemonnier Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Gordon Waldron Chief Financial Officer & Chairman
Magdalena Zalacain Chief Scientific Officer
You’re viewing 3 of 5 executive team members. Get the full list »

Antabio Board Members (16)

Name Representing Role Since
Adriano Ali Antabio Board Observer 000 0000
Christophe Ricard Antabio Board Member 000 0000
Claire Poulard Omnes Capital Board Member 000 0000
Geoff Lawton Self Board Observer 000 0000
Gordon Waldron Antabio Chief Financial Officer & Chairman 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Antabio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antabio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Innovation Council Fund Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
BNP Paribas Développement PE/Buyout Minority 000 0000 000000 0
Galia Gestion PE/Buyout Minority 000 0000 000000 0
IRDI Capital Investissement Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial